크레오에스지

040350KOSDAQ

41.5 / 100

Reference Date: 2026-10-23

Financial Score15.0 / 40

News Sentiment12.5 / 25

Momentum2.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 31.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Creo SG operates in three main business segments: financial IT solutions, biotech vaccine development, and real estate operations. The solution segment provides core banking systems to banks and non-banks, while the biotech segment focuses on developing vaccines for AIDS, COVID-19, and superbugs, though it currently generates no revenue. The real estate segment manages properties through a subsidiary.

Number of Employees

48people

Average Salary

57.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.15Industry Average 1.204.0Point

In line with industry avg

ROE

-17.52Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

69.35Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼32.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -30.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (19%, downtrend)

Current 2,735Won52-week high 11,95052-week low 556

1-month return0.0Point

1m -31.11% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 1Neutral 5Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-10-22
Neutral[기재정정]금전대여결정2026-10-15
Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-10-15
Neutral타법인주식및출자증권취득결정2026-10-15
Neutral주식등의대량보유상황보고서(일반)2026-10-12